초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 03월 02일 17시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

제117회 대한화학회 학술발표회, 총회 및 기기전시회 안내 Synthesis and Biological Evaluation of Hsp90 inhibitor against Drug-resistant Cancer Cells

2016년 2월 18일 16시 33분 53초
MEDI.P-467 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
4월 22일 (금요일) 13:00~14:30
저자 및
박선유, 서영호1,*
계명대학교 약학과, Korea
1계명대학교 약학대학, Korea
Over the past two decades, molecularly targeted therapies have been discovered to more accurately identify and attack cancer cells, while causing little damage to normal cells. These “one disease-one target approach” are prevalent paradigm in pharmaceutical industry and several targeted drugs such as Gleevec (Novartis), Herceptin (Genentech) and Iressain (AstraZeneca) have been approved by FDA for the treatment of cancers. Despite their superiority in their therapeutic efficacy and selectivity, recent evidence has shown that most single-target drugs encounter the emergence of drug resistance in long-term use. The tumor cells outsmart single-target drugs to escape from their destiny by mutating target protein or finding new pathway to achieve tumor growth that does not depend on target protein. In this regard, heat shock protein 90 (Hsp90) has emerged as an attractive therapeutic target in cancer research. Hsp90 is an ATP dependent molecular chaperone that is required for the stability and maturation of numerous ‘client’ proteins. These client proteins include EGFR, Her2, Met, Cdk4, Akt, Hif-1, all of which are known to be involved in various signaling pathways for the survival, proliferation, invasion and metastasis of cancer cell. Accordingly, the inhibition of Hsp90 function promotes ubiquitin-dependent proteasomal degradation of diverse client proteins, which can eventually overcome the drug resistance and lead to cell death. As part of our ongoing efforts to discover small molecules targeting N-terminal ATP-binding pocket of Hsp90, we had performed a structure-based drug design (SBDD) of small molecule inhibitors, synthesized and evaluated their biological activities against Hsp90. Here, we present our effort to develop therapeutic agents against Hsp90.